This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Sprycel

Bristol-Myers Squibb Company

Drug Names(s): BMS-354825, NSC-732517, dasatinib

Description: Sprycel is a rationally designed oral investigational agent that inhibits five tyrosine kinase proteins including BCR/ABL and SRC proteins.

In vitro studies have shown that BMS-354825 is 100-fold more potent than Gleevec (imatinib) and has demonstrated efficacy against 14 of 15 imatinib resistant BCR-ABL mutants.

Deal Structure: In April 2009, Bristol-Myers Squibb and Otsuka Pharmaceutical have established an oncology collaboration for SPRYCEL and IXEMPRA.

Beginning in 2010, Bristol-Myers Squibb and Otsuka will collaborate on two oncology assets SPRYCEL and IXEMPRA as follows:

  • Otsuka will share in commercial expenses for the U.S., Europe and Japan and co-promote SPRYCEL with Bristol-Myers Squibb in the U.S., Japan and major EU markets;
  • Bristol-Myers Squibb will pay Otsuka a collaboration fee on aggregate annual net sales of SPRYCEL and IXEMPRA beginning in 2010 on a regressive tiering basis through 2020.
In March 2015, Otsuka Pharmaceutical and Bristol-Myers Squibb have agreed to end the co-promotion arrangements for the drug SPRYCEL (generic name: dasatinib) in Japan, effective from February 27, 2015. Otsuka Pharmaceutical will continue to receive a specified collaboration fee for SPRYCEL net sales in the U.S., Europe (France, Germany, Italy, Spain and the U.K.), and Japan. There...See full deal structure in Biomedtracker

Partners: Otsuka Holdings Co., Ltd.


Sprycel News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug